A Synthetic Biology-driven, high throughput approach to vaccine design
Lead Research Organisation:
University of Manchester
Department Name: Life Sciences
Abstract
Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.
Organisations
People |
ORCID iD |
| Jeremy Paul Derrick (Principal Investigator) |
| Description | The award funded a commercial assessment, conducted by an external consultant, into a novel technology for the use of virus-like particles in vaccine development. The findings were that there was potential for commercial development but that particular attention needed to be paid to the precise manner of application- the target disease, its testing and pathway of development. |
| Exploitation Route | The funding outcomes are currently being used in further development of more advanced technologies which are currently being evaluated by the applicant's technology transfer organisation. |
| Sectors | Healthcare,Pharmaceuticals and Medical Biotechnology |
| Description | The findings from the report have been used to inform and guide the next stage in the development pathway for this technology. This has resulted in additional funding to support practical work which will underpin and extend the original invention. |
| First Year Of Impact | 2015 |
| Sector | Healthcare,Pharmaceuticals and Medical Biotechnology |
| Description | MRC Confidence in Concept |
| Amount | £37,097 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 09/2015 |
| End | 05/2016 |